AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AEON Biopharma, Inc. on April 3, 2025, covering events reported as of that date. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Irvine, California. The filing primarily addresses executive leadership changes under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Executive Leadership: The Board formally appointed Jost Fischer, the current Chairman of the Board, as Interim President, Chief Executive Officer, and principal executive officer, effective April 4, 2025. This follows a prior announcement on March 27, 2025, naming him Interim CEO.
- Financial Leadership: The Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025. Ms. Sy previously served as Vice President, Corporate Controller since August 2023.
- Compensation Adjustment: In connection with her promotion, Ms. Sy's base salary was increased from $245,000 to $275,000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, or specific risks. It confirms there are no related person transactions or family relationships between Ms. Sy and the Company's directors or officers requiring disclosure.
Investor Verification Checklist
- Verify the effective date of the new executive appointments (April 4, 2025).
- Review the prior Form 8-K filed on March 27, 2025, for context on the initial Interim CEO designation.
- Confirm the absence of undisclosed related party transactions involving the new officers.
- Monitor upcoming periodic reports (10-Q/10-K) for financial data, as this 8-K contains none.